secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001193125-25-323787
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports 21% ORR for WTX-124 in melanoma, seeks partnerships for INDUKINE programs
--------------------------------------------------------------------------------

- WTX-124 monotherapy achieved 21% ORR in heavily pretreated advanced melanoma; 30% ORR in patients not primary resistant to prior immunotherapy.
- FDA accepted 18 mg as recommended dose for WTX-124; provided guidance for registration path in post-ICI advanced melanoma.
- WTX-330 showed one confirmed partial response in metastatic gall bladder cancer with 45% tumor reduction; favorable tolerability.
- Company shifting focus to INDUCER T-cell engager platform; IND filings for WTX-1011 (STEAP1) and WTX-2022 (CDH6) planned mid-2027 pending funding.
- Additional funding required to initiate further development of both INDUKINE and INDUCER programs; seeking strategic partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312525323787/0001193125-25-323787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312525323787/d21464d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-323787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer